G
358570
vs
K
KOSPI 200
Over the past 12 months, GI Innovation Inc has underperformed KOSPI 200, delivering a return of +7% compared to the KOSPI 200's +110% growth.
Stocks Performance
358570 vs KOSPI 200
Performance Gap
358570 vs KOSPI 200
Performance By Year
358570 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.